Our data may have important clinical implications as they suggest for the first time that rescuing the EGFR inhibitory effect of AT1 receptor antagonists or diabetes and/or ischemia by activators of the EGF/EGFR pathway may represent a novel clinical approach to improve protection against end-organ damage in diabetic hearts. The gene discussed is EGFR; the disease is diabetes mellitus.